At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 408 enrolled
Drug / intervention
Pridopidine +1 moredrug
Likely dose
Pridopidine 22.5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Dose-Finding, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled Study, Evaluating the Safety and Efficacy of Pridopidine 45, 67.5, 90, and 112.5 mg Twice-Daily vs Placebo for Symptomatic Treatment in Patients With Huntington's Disease
In Brief
A Phase 2 clinical trial evaluating Pridopidine and Placebo for Huntington's Disease. Completed, enrolled 408 participants across 58 sites in 12 countries.
Detailed Summary
This is a multicenter, multinational, randomized, parallel-group, double-blind, placebo-controlled, dose range finding study to compare the efficacy and safety of different doses of pridopidine versus placebo in the treatment of motor impairment in Huntington's Disease (HD).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHuntington's Disease
CountriesAustralia, Austria, Canada, Denmark, France, Germany, Italy, Netherlands, Poland, Russia, United Kingdom, United States
CollaboratorsEuropean Huntington's Disease Network, Huntington Study Group
Timeline
Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedDec 2013
Enrollment StartFeb 2014
Primary CompletionDec 2015
Study CompletionJul 2016
TodayJul 2026
First PostedDec 10, 2013
Enrollment StartFeb 28, 2014
Primary CompletionDec 16, 2015
Study CompletionJul 7, 2016
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 12.6 years ago
Interventions
Pridopidinedrug
22.5 mg and 45 mg capsules
Placeboother
Capsules matching drug